HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction.

AbstractBACKGROUND:
There are limited data regarding factors associated with spontaneous left ventricular reverse remodeling (S-LVRR) among mildly symptomatic heart failure (HF) patients and its prognostic implications on clinical outcomes.
METHODS AND RESULTS:
Best subsets logistic regression analysis was used to identify factors associated with S-LVRR (defined as ≥15% reduction in left ventricular end-systolic volume at 1-year of follow-up) among 612 patients treated with internal cardioverter defibrillator-only therapy in Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) and to create a score for the prediction of S-LVRR. Cox proportional hazards regression modeling was used to assess the clinical outcome of all internal cardioverter defibrillator-only patients (n=714) with a high S-LVRR score. S-LVRR occurred in 25% of internal cardioverter defibrillator-only patients. Predictors of S-LVRR included systolic blood pressure≥140 mm Hg, serum creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonischemic cardiomyopathy. Multivariate analysis showed that each 1-point increment in S-LVRR score (range, 0-7) was associated with an 11% (P=0.019) reduction in the risk of HF or death. Treatment with cardiac resynchronization therapy was associated with a significant reduction in the risk of HF or death only among internal cardioverter defibrillator-treated patients with a low (Q1-3) S-LVRR score (hazard ratio=0.55; P<0.001), but not among those with a higher (Q4) score (hazard ratio=1.06; P=0.72).
CONCLUSIONS:
Our data suggest that approximately one quarter of mild HF patients eligible for biventricular pacing experience S-LVRR. Combined assessment of clinical factors associated with S-LVRR can be used to identify mild HF patients with a low risk for clinical events without cardiac resynchronization therapy intervention.
CLINICAL TRIAL REGISTRATION URL:
http://www.clinicaltrials.gov. Unique identifier: NCT00180271.
AuthorsAndrew Brenyo, Alon Barsheshet, Valentina Kutyifa, Anne-Christine Ruwald, Mohan Rao, Wojciech Zareba, Anne-Catherine Pouleur, Dorit Knappe, Scott D Solomon, Scott McNitt, David T Huang, Arthur J Moss, Ilan Goldenberg
JournalCirculation. Heart failure (Circ Heart Fail) Vol. 7 Issue 4 Pg. 565-72 (Jul 2014) ISSN: 1941-3297 [Electronic] United States
PMID24786217 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2014 American Heart Association, Inc.
Topics
  • Aged
  • Canada (epidemiology)
  • Defibrillators, Implantable
  • Echocardiography
  • Europe (epidemiology)
  • Female
  • Heart Failure (mortality, physiopathology, therapy)
  • Heart Ventricles (diagnostic imaging, physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Risk Factors
  • Stroke Volume (physiology)
  • Survival Rate (trends)
  • United States (epidemiology)
  • Ventricular Dysfunction, Left (mortality, physiopathology, therapy)
  • Ventricular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: